Cell and gene therapy: a snapshot of investor perspectives

Published:December 03, 2020DOI:


      In a collaborative effort between the Commercialization Committee of the International Society for Cell & Gene Therapy (ISCT) and Bloomberg Intelligence, a broad survey of the investment community was executed in order to understand investor perceptions of companies that develop cell and gene therapies (CGTs) and gauge the trajectory of future investment. A broad spectrum of investors responded to the survey, including both health care specialists and generalist investors across a wide range of fund sizes and geographies. A majority of survey respondents have limited exposure to CGTs in their health care portfolios today, which highlights the opportunity to increase awareness of this burgeoning field in the investment community. The survey established that clinically significant data are the most important consideration when making an investment in this area, whereas safety concerns were highlighted as the most prominent barrier to making an investment. Challenges with manufacturing and scale-up were also ranked as a significant concern. The majority of investors hold the belief that both autologous and allogeneic cell therapies can co-exist. The detailed findings of this survey will help to provide a foundation for educational content that the ISCT Commercialization Committee can bring forth to further the investment in CGTs through the newly created Investigators to Investors program.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Alliance for Regenerative Medicine. Advancing Gene, Cell & Tissue Based Therapies. 2019 ARM Annual Report & Sector Year in Review,; 2020 [accessed November 6, 2020].

        • Tang
        The global pipeline of cell therapies for cancer.
        Nature Drug Discovery. 2019; 18: 821-822
        • Quinn
        Estimating the Clinical Pipeline of Cell and Gene Therapies and Their Potential Economic Impact on the US Healthcare System.
        Value Health. 2019; 22: 621-626
        • Brudno and Kochenderfer
        Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management.
        Blood Rev. 2019; 34: 45-55
        • Braendstrup
        The long road to the first FDA approved gene therapy: chimeric antigen receptor T cells targeting CD19.
        Cytotherapy. 2020; 22: 57-69
        • Cuende
        Cell, tissue and gene products with marketing approval.
        Cytotherapy. 2018; 20: 1401-1413